<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00502047</url>
  </required_header>
  <id_info>
    <org_study_id>PLAN-EC-HIPERL-02</org_study_id>
    <secondary_id>EudraCT number: 2004-002184-24</secondary_id>
    <nct_id>NCT00502047</nct_id>
  </id_info>
  <brief_title>Effect of the Plantago Ovata Husk on the Lipid Profile of Patients With Hypercholesterolemia</brief_title>
  <official_title>Multicentre, Comparative, Double-Blind, Two-Arm Parallel Clinical Trial of the Effects of Treatment With Plantago Ovata Husk on the Lipid Profile of Patients With Hypercholesterolemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rottapharm Spain</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rottapharm Spain</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hypothesis of this study is that soluble fibre may contribute to a reduction of the low
      density lipoprotein cholesterol (LDL-c), and the combined effect with a statin may achieve an
      optimisation of the cholesterol-lowering effects in adults with several cardiovascular risk
      factors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It has been demonstrated that high concentrations of cholesterol and low density lipoprotein
      cholesterol (LDL, high risk cholesterol) are the major risk factors for heart disease,
      myocardial infarction and angina pectoris. Moreover, these conditions represent the major
      cause of death in the Western world.

      Of the measures established to reduce blood cholesterol levels, the introduction of
      consumption of dietary fibre is a novelty. The term dietary fibre defines a variety of
      substances that are found in plants and are resistant to digestion by human gastrointestinal
      enzymes.

      The studies performed up until now to determine the effects of fibre on blood lipids have
      demonstrated that consumption of soluble fibre can reduce cholesterol.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">July 2007</completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the capacity to reduce by 5% the concentrations of plasma LDL-c by treatment with soluble fibre-Plantago ovata husk- added to a low saturated fat diet in patients with moderate hypercholesterolemia.</measure>
    <time_frame>16 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To study the combined cholesterol lowering effect of treatment with Plantago ovata husk and statins to achieve the therapeutic objective</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To analyse the effect of Plantago ovata husk fibre on blood pressure</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate whether the response on plasma lipids is modulated by the polymorphisms of apolipoprotein E, cholesterol ester transfer protein (CETP), apolipoprotein A-V and Fatty acid binding protein 2 (FABP2)</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">255</enrollment>
  <condition>Hypercholesterolemia</condition>
  <condition>Cardiovascular Disease</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Plantago ovata husk</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Levels of LDL-c between &gt;130 mg/dl and &lt;189 mg/dl

          -  Presence at least 1 of the cardiovascular risk factor defined as:

          -  age above 45 years in men and 55 years in women

          -  smoker

          -  high blood pressure

          -  HDL-c &lt; 40 mg/dl in men and &lt;46 mg/dl in women

          -  family background of early heart disease

          -  Patients who have given informed consent

          -  Patients who will be capable of following diet guidelines

        Exclusion Criteria:

          -  Triglycerides &gt;350 mg/dl

          -  History of cardiovascular disease

               -  treatment with statins prior to the beginning of the trial and who have not
                  dropped out at least 2 months before the beginning of the study

          -  Diabetes mellitus
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rosa Solà, MD, phD</last_name>
    <role>Study Chair</role>
    <affiliation>Hosp. Universitario San Joan de Reus , Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Manuel Castro, MD, phD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hosp. Saint Franciscus Gasthuis, Rotterdam (Netherlands)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eric Brucker, MD, phD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hosp. de la Pitié, Paris (France)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mª Cruz Almaraz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hosp. Universitario Carlos Haya, Málaga (Spain)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xavier Luque, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centro de Atención Primaria Alcover, Tarragona (Spain)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>José Vicente Vaquer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centro de Salud Petrer I, Alicante (Spain)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Luis de Teresa, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hosp. San Vicente de Raspeig, Alicante (Spain)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Silvia Narejos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centro de Atención Primaria Centelles, Barcelona (Spain)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xavier Farrés, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centro de Atención Primaria El Remei, Vic, Barcelona (Spain)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>José Miguel Martínez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centro de Salud Tomás Ortuño, Benidorm, Alicante (Spain)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hosp. Universitario San Joan de Reus, (Spain)</name>
      <address>
        <city>Reus</city>
        <state>Tarragona</state>
        <zip>43201</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>July 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 16, 2007</study_first_submitted>
  <study_first_submitted_qc>July 16, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 17, 2007</study_first_posted>
  <last_update_submitted>July 16, 2007</last_update_submitted>
  <last_update_submitted_qc>July 16, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 17, 2007</last_update_posted>
  <keyword>plantago ovata husk</keyword>
  <keyword>soluble fibre</keyword>
  <keyword>hypercholesterolemia</keyword>
  <keyword>cardiovascular risk factor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

